Vyome Holdings Files 8-K: Material Agreement & Accountant Change

TL;DR

Vyome Holdings (VYME) filed an 8-K for a material agreement and auditor change. Keep an eye on this.

AI Summary

Vyome Holdings, Inc. filed an 8-K on August 20, 2025, reporting a material definitive agreement and changes in its certifying accountant. The filing date indicates events occurred on or before August 18, 2025. The company, previously known as ReShape Lifesciences Inc. and OBALON THERAPEUTICS INC, is incorporated in Delaware and operates in the Pharmaceutical Preparations sector.

Why It Matters

This filing signals significant corporate activity, including a new material agreement and a change in auditors, which could impact the company's financial reporting and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements and changes in certifying accountants can indicate significant operational or financial shifts that warrant closer scrutiny.

Key Players & Entities

• Vyome Holdings, Inc. (company) — Registrant
• ReShape Lifesciences Inc. (company) — Former Company Name
• OBALON THERAPEUTICS INC (company) — Former Company Name
• 20250818 (date) — Earliest event reported
• 20250820 (date) — Filing date

FAQ

Key Financial Figures

• $0.001 — ch registered Common stock, par value $0.001 per share HIND The Nasdaq Capital M
• $12,000,000 — spect to the issuance and sale of up to $12,000,000 of the Company's shares of common stock
• $3,420,926 — e offered and sold in the Offering from $3,420,926 to $12,000,000. The Shares will be sol

Filing Documents

• ea0253846-8k_vyome.htm (8-K) — 44KB
• ea025384601ex1-1_vyome.htm (EX-1.1) — 25KB
• ea025384601ex5-1_vyome.htm (EX-5.1) — 7KB
• ea025384601ex16-1_vyome.htm (EX-16.1) — 3KB
• ex5-1_001.jpg (GRAPHIC) — 5KB
• ex16-1_001.jpg (GRAPHIC) — 16KB
• ex16-1_002.jpg (GRAPHIC) — 18KB
• 0001213900-25-079045.txt ( ) — 312KB
• hind-20250818.xsd (EX-101.SCH) — 3KB
• hind-20250818_lab.xml (EX-101.LAB) — 33KB
• hind-20250818_pre.xml (EX-101.PRE) — 22KB
• ea0253846-8k_vyome_htm.xml (XML) — 4KB

01 Entry into a Material Definitive

Item 1.01 Entry into a Material Definitive Agreement. On August 20, 2025, Vyome Holdings, Inc. (f/k/a ReShape Lifesciences Inc.) (the "Company") entered into Amendment No. 1 (the "Amendment") to that certain Equity Distribution Agreement dated May 30, 2025 (the "Sales Agreement") with Maxim Group LLC ("Maxim") to act as the Company's exclusive sales agent with respect to the issuance and sale of up to $12,000,000 of the Company's shares of common stock, par value $0.001 per share (the "Shares"), from time to time, in an at-the-market public offering (the "Offering"). The Amendment increases the amount that may be offered and sold in the Offering from $3,420,926 to $12,000,000. The Shares will be sold and issued pursuant the Company's shelf registration statement on Form S-3 (File No. 333-287168), which was previously declared effective by the Securities and Exchange Commission, and a related prospectus, as supplemented. The Company is simultaneously herewith filing a supplement to the prospectus supplement with the Securities and Exchange Commission to increase the number of Shares that may be offered and sold in the Offering.

01 Changes in Registrant's Certifying Accountant

Item 4.01 Changes in Registrant's Certifying Accountant On August 18, 2025, Haskell & White LLP ("Haskell"), was dismissed as the independent registered public accounting firm of the Company, formerly ReShape Lifesciences Inc. Effective as of August 18, 2025 Kreit & Chiu CPA LLP ("Kreit & Chiu") was appointed to serve as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2025. The decision to change auditors was approved and recommended by the Company's Audit Committee and approved by its Board of Directors. During the fiscal year ended December 31, 2024 and the subsequent interim period through August 18, 2025, the date of the dismissal of Haskell, there were no disagreements with Haskell, on any matter of accounting principles or practices, financial statement disclosure or auditing scope or procedure, which disagreements, if not resolved to the satisfaction of Haskell would have caused it to make reference to the qualified or modified as to uncertainty, audit scope, or accounting principle except that Haskell's report for the fiscal year ended December 31, 2024 contained an explanatory paragraph regarding the existence of substantial doubt about the Company's ability to continue as a going concern. Also, with respect to ReShape Lifesciences Inc., there were no "reportable events" within the meaning of Item 304(a)(1)(v) of Regulation S-K, except for material weaknesses in the Company's internal control over financial reporting as of December 31, 2024, as reported in Part II, Item 9A of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024. RSM US LLP audited the consolidated financial statements of ReShape Lifesciences Inc.as of December 31, 2023, and for the year ended December 31, 2023. During the two fiscal years ended December 31, 2024 and 202

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Amendment to Equity Distribution Agreement dated August 20, 2025. 5.1 Opinion of Sichenzia Ross Ference Carmel LLP 16.1 Letter from Haskell & White LLP as to the change in certifying accountant, dated August 18, 2025. 23 .1 Consent of Sichenzia Ross Ference Carmel LLP (included in the opinion filed as Exhibit 5.1). 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. VYOME HOLDINGS, INC. August 20, 2025 By: /s/ Venkat Nelabhotla Name: Venkat Nelabhotla Title: Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR